Literature DB >> 11916555

Overexpression of pyrimidine nucleoside phosphorylase enhances the sensitivity to 5'-deoxy-5-fluorouridine in tumour cells in vitro and in vivo.

T Nagata1, M Nakamori, M Iwahashi, H Yamaue.   

Abstract

5-Fluorouracil (5-FU) and 5'-deoxy-5-fluorouridine (5'-DFUR), a prodrug of 5-FU, are representative of the chemotherapeutic agents for colorectal adenocarcinomas. Pyrimidine nucleoside phosphorylase (PyNPase) catalyses the conversion of 5'-DFUR to 5-FU, the activated form. Murine adenocarcinoma CT26 cells were transfected with human PyNPase cDNA. The engineered transfectants producing PyNPase augmented the response to 5'-DFUR in vitro and in vivo. Animals were administered by means of intraperitoneal (i.p.) injection, and not orally, in order to obtain a better efficiency of absorption. The tumours of the transfected cells nearly all disappeared, even following treatment with quite a small amount of the anticancer agent. The animals injected with the tranfected cells were protected against subsequent challenge with the parental tumour cell line. These findings demonstrate that PyNPase gene transfection increases the sensitivity to 5'-DFUR, and thereby decreases the toxicity of the agent.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11916555     DOI: 10.1016/s0959-8049(01)00469-5

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  5 in total

1.  5-Fluorouracil concentration in blood, liver and tumor tissues and apoptosis of tumor cells after preoperative oral 5'-deoxy-5-fluorouridine in patients with hepatocellular carcinoma.

Authors:  Jin-Fang Zheng; Hai-Dong Wang
Journal:  World J Gastroenterol       Date:  2005-07-07       Impact factor: 5.742

2.  Tumor-specific expression of shVEGF and suicide gene as a novel strategy for esophageal cancer therapy.

Authors:  Ting Liu; Hai-Jun Wu; Yu Liang; Xu-Jun Liang; Hui-Chao Huang; Yan-Zhong Zhao; Qing-Chuan Liao; Ya-Qi Chen; Ai-Min Leng; Wei-Jian Yuan; Gui-Ying Zhang; Jie Peng; Yong-Heng Chen
Journal:  World J Gastroenterol       Date:  2016-06-21       Impact factor: 5.742

3.  Adenovirus-mediated prodrug-enzyme therapy for CEA-producing colorectal cancer cells.

Authors:  Satoshi Okabe; Takehiro Arai; Hironori Yamashita; Kenichi Sugihara
Journal:  J Cancer Res Clin Oncol       Date:  2003-06-03       Impact factor: 4.553

4.  Research development of the relationship between thymidine phosphorylase expression and colorectal carcinoma.

Authors:  Dian-Jun Ye; Ji-Min Zhang
Journal:  Cancer Biol Med       Date:  2013-03       Impact factor: 4.248

Review 5.  Bystander or no bystander for gene directed enzyme prodrug therapy.

Authors:  Gabi U Dachs; Michelle A Hunt; Sophie Syddall; Dean C Singleton; Adam V Patterson
Journal:  Molecules       Date:  2009-11-10       Impact factor: 4.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.